Intervention not reported
Cyclosporine A plus mycophenolate plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Everolimus · people undergoing liver transplantation
It is very uncertain whether the intervention changes everolimus (very low certainty).
1 finding from 1 review
Intervention not reported
Tacrolimus plus azathioprine · people undergoing liver transplantation
It is very uncertain whether the intervention changes tacrolimus plus azathioprine (very low certainty).
1 finding from 1 review
Intervention not reported
Tacrolimus plus everolimus · people undergoing liver transplantation
It is very uncertain whether the intervention changes tacrolimus plus everolimus (very low certainty).
1 finding from 1 review
All‐cause mortality · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether antioxidants changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Short‐term mortality (< 1 year) · people with acute HBV infection
It is very uncertain whether lamivudine changes short‐term mortality (< 1 year) compared with no intervention (very low certainty).
1 finding from 1 review
Progression to fulminant HBV infection · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with acute HBV infection
1 finding from 1 review
Adverse events (proportion) (4 to 6 months) · people with acute HBV infection
Interferon may leads to higher adverse events (proportion) (4 to 6 months) compared with no intervention (low certainty).
1 finding from 1 review